Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Biologic Markets
- Blood-Related Disorders
- Alfimeprase (Nuvelo/Amgen' s Cardiovascular Fibrinolytic)
- Desmoteplase (Paion/Forest/Lundbeck' s Bat-Plasminogen Activator)
- Micera (Roche' s Methoxy Polyethylene Glycol-Epoetin Beta)
- Nplate (Amgen' s Romiplostim)
- Tifacogin (Novartis' s Tissue Factor Pathway Inhibitor)
- Viprinex (Neurobiological Technologies' Ancrod)
- Cardiovascular Recombinant Proteins
- Recombinant Proteins for Central Nervous System Diseases
- Cancer-Related Recombinant Protein Drugs
- Aflibercept (Sanofi-Aventis/Regeneron/Bayer HealthCare' s Vascular
Endothelial Growth Factor Trap)
- Onconase (Alfacell/Par Pharmaceutical' s Ranpirnase)
- TransMID (Xenova/Nycomed/Sosei' s Transferrin-CRM107, or Tf-CRM107)
- Biosimilar G-CSFs
- Complexity in the Marketplace
- Antidiabetic Recombinant Proteins
- Novel Glucagon-Like Peptide 1 Analogues
- Alkermes/Amylin/Eli Lilly' s Exenatide LAR
- New Delivery Angles
- Pfizer' s Exubera
- Novo Nordisk/Aradigm' s AERx Inhaled Insulin
- Eli Lilly/Alkermes' s AIR Inhaled Insulin
- MannKind' s Technosphere Inhaled Insulin
- Generex Biotechnology' s Oral-Lyn, a Buccal Insulin
- Musculoskeletal Recombinant Proteins
- Phase III Recombinant Proteins for Other Diseases
- Albuferon (Albinterferon Alfa-2b)
- ZymoGenetics/Merck Serono' s Atacicept (TACI-Ig)
- Changing of the Guard
- Amgen Feels the Heat as Pressures Mount
- Evolving Business Strategies and a Rising Star
- Decision Resources, Inc., Analysts Featured
- Mary Argent-Katwala, Ph.D., Therapeutic Area Director, Onkos
- Marcus Bain, Ph.D., Analyst, Metabolic and Cardiovascular Disorders
- Madhuri Borde, Ph.D., Project Director, Treatment Algorithms
- Sami R. Fam, Ph.D., Analyst, Cognos
- Michael Latwis, M.B.A., Corporate Analyst, Pharmaview
- John M. Lebbos, M.D., Vice President, Decision Resources, Inc.
- Andrew Merseth, Senior Business Analyst
- Jonathan W. Searles, Analyst, Cognos
- Amy H. Whiting, Ph.D., Analyst, Immune and Inflammatory Disorders
- Donny Wong, Ph.D., Principal Analyst, Metabolic Disorders
Tables
- 1. Select Recombinant Proteins in Late-Stage Clinical Development for
Blood-Related Disorders
- 2. Select Cardiovascular Recombinant Proteins in Clinical Development
- 3. Select Central Nervous System Recombinant Proteins in Clinical
Development
- 4. Select Anticancer Recombinant Proteins in Clinical Development
- 5. Recombinant Protein Development Programs Announced by Major Biosimilar
Developers
- 6. Select Antidiabetic Recombinant Proteins in Phase III Development
- 7. Select Musculoskeletal Recombinant Proteins in Clinical Development
- 8. Select Recombinant Proteins in Phase III Development
Figures
- 1. Evolving Pharmaceutical Market Segments Based on Technology, 2000-2012
- 2. Top-Selling Recombinant Protein Brands, 2007
- 3. Number of Recombinant Proteins in Clinical Development, 2007
- 4. Recombinant Proteins in Clinical Development by Therapeutic Category,
2007
- 5. Rho Kinase Pathway: The GTPase Molecular Switch
- 6. Sales of Five Amgen Brands, 2002-2013
- 7. Role of GLP-1 in Glucose Metabolism
- 8. Amgen Financial Analysis, 1988-2006
|
Related Report
|
View Cart
